JMP Securities reissued their outperform rating on shares of Cytokinetics, Incorporated (NASDAQ:CYTK) in a research report released on Tuesday, The Fly reports. JMP Securities currently has a $13.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $17.00. The analysts noted that the move was a valuation call.

CYTK has been the topic of several other reports. Needham & Company LLC reaffirmed a buy rating and set a $22.00 target price on shares of Cytokinetics, in a report on Sunday, September 17th. BidaskClub raised Cytokinetics, from a hold rating to a buy rating in a report on Tuesday, July 25th. Morgan Stanley began coverage on Cytokinetics, in a report on Monday, July 31st. They set an overweight rating and a $24.00 target price on the stock. Zacks Investment Research downgraded Cytokinetics, from a buy rating to a hold rating in a report on Thursday, August 17th. Finally, Piper Jaffray Companies reaffirmed an overweight rating and set a $18.00 target price on shares of Cytokinetics, in a report on Tuesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. Cytokinetics, presently has a consensus rating of Buy and a consensus target price of $17.64.

Cytokinetics, (NASDAQ CYTK) opened at $7.97 on Tuesday. Cytokinetics, has a twelve month low of $7.00 and a twelve month high of $17.20. The company has a quick ratio of 7.60, a current ratio of 7.60 and a debt-to-equity ratio of 0.14.

Cytokinetics, (NASDAQ:CYTK) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.04. The firm had revenue of $6.18 million for the quarter, compared to the consensus estimate of $5.35 million. Cytokinetics, had a negative return on equity of 62.64% and a negative net margin of 172.27%. analysts predict that Cytokinetics, will post -2.4 earnings per share for the current year.

WARNING: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2017/11/24/cytokineticss-cytk-outperform-rating-reiterated-at-jmp-securities.html.

In other news, insider Caryn Gordon Mcdowell sold 4,260 shares of Cytokinetics, stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $12.94, for a total value of $55,124.40. Following the completion of the transaction, the insider now directly owns 17,982 shares of the company’s stock, valued at approximately $232,687.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Bradley Paul Morgan sold 118,330 shares of Cytokinetics, stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $15.00, for a total value of $1,774,950.00. Following the completion of the transaction, the senior vice president now directly owns 63,107 shares of the company’s stock, valued at $946,605. The disclosure for this sale can be found here. Over the last three months, insiders sold 178,223 shares of company stock valued at $2,639,239. Corporate insiders own 7.20% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. State of Alaska Department of Revenue bought a new position in shares of Cytokinetics, in the 2nd quarter worth about $109,000. Municipal Employees Retirement System of Michigan bought a new position in shares of Cytokinetics, in the 2nd quarter worth about $132,000. Birchview Capital LP bought a new position in shares of Cytokinetics, in the 3rd quarter worth about $145,000. Piedmont Investment Advisors LLC bought a new position in shares of Cytokinetics, in the 3rd quarter worth about $159,000. Finally, BNP Paribas Arbitrage SA raised its position in shares of Cytokinetics, by 4,464.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,328 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 13,036 shares in the last quarter. 71.92% of the stock is owned by hedge funds and other institutional investors.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

The Fly

Analyst Recommendations for Cytokinetics, (NASDAQ:CYTK)

Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.